Predict your next investment

Corporation
HEALTHCARE

See what CB Insights has to offer

Stage

Acquired | Acquired

Total Raised

$8M

Valuation

$0000 

About Cocensys

Development of CNS drugs targeted at CNS receptors. Acquired by Purdue Pharma

Cocensys Headquarter Location

213 Technology Drive

Irvine, California, 92618,

United States

949-753-6100

Latest Cocensys News

CoCensys Begins Preclinical Development of NMDA Antagonist

Mar 15, 2017

CoCensys Inc. (Irvine, CA) announced today that Parke-Davis, a division of Warner-Lambert Co. (Morris Plains, NJ), has advanced its lead compound into preclinical development for the treatment of neurological disorders. This compound is an antagonist to N-methyl-D-aspartate (NMDA) receptors in the brain. NMDA receptors have long been recognized as promising molecular targets for the treatment of neurological disorders such as stroke, traumatic brain injury, epilepsy, Parkinson's disease, and chronic pain states. The first generation of NMDA receptor antagonists that blocked the receptor channel directly produced unacceptable side effects, such as induction of psychotomimetic (PCP-like) behaviors and neurotoxicity. Subsequent studies at the molecular level demonstrated the heterogeneity of NMDA receptors, which consist of subtypes with distinct biophysical and pharmacologic properties and different patterns of distribution in the brain. While the first generation of NMDA receptor antagonists were non-selective, the collaboration between CoCensys and Parke-Davis sought to design drugs that interact selectively with specific subtypes of NMDA receptors. The intent was to retain the potential therapeutic utility of an NMDA receptor antagonist while greatly improving the side-effect profile. "The subtype-selective antagonists appear to have therapeutic potential for a variety of neurological disorders," said Richard Woodward, senior director of drug discovery at CoCensys. "We believe from our animal studies that these types of compounds have superior behavioral and side effect profiles to channel blockers such as dizocilpine (MK-801) and competitive antagonists such as selfotel (CGS 19755)." CoCensys is a biopharmaceutical company that discovers and develops products for the treatment of neurological and psychiatric disorders. For more information: Richard Woodward, Senior Director of Drug Discovery, CoCensys Inc., 201 Technology Dr., Irvine, CA 92618. Tel: 949-753-6100. Fax: 949-753-6161. Like what you are reading? Sign up for our free newsletter SIGN ME UP By clicking Sign Me Up, you agree to our Terms and that you have read our Privacy Policy .

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.